SOUNDTRACK-D2: A study to test AZD0486 first line therapy for elderly or unfit people with large B-cell lymphoma

This trial aims to see how effective and safe treatment with R-mini-CHOP × 2, followed by a new treatment called AZD0486, is in elderly or unfit participants newly diagnosed with large B-cell lymphoma (LBCL).

You can share the following clinicaltrials.gov identifier with your medical team so they can find out more about the trial: NCT07215585

Trial aim and background

The aim of this trial is to measure the efficacy and safety of treatment with AZD0486, a bispecific antibody. The trial will test treatment with R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6 in elderly or unfit participants newly diagnosed with LBCL.

Who can enter

Adults aged 80 years old or over, or adults aged 65 years old or over and classified as unfit using a specific tool, might be eligible to take part. Participants must not be considered suitable for treatment with full-dose R-CHOP. 

Locations

Recruitment is taking place at the following UK locations:

  • London
  • Newcastle upon Tyne

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT07215585

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.